Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation
- PMID: 16162102
- DOI: 10.1111/j.1432-2277.2005.00191.x
Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation
Abstract
New onset diabetes mellitus (NODM) affects kidney transplantation outcome. Several risk factors, including immunosuppressive drug levels, are related with NODM development. This analysis evaluates the incidence and risk factors of NODM in kidney transplant patients receiving tacrolimus, taking into account 6-month blood levels and concentration-dose ratios (CDRs). Seventy-six patients under tacrolimus therapy who received a cadaveric renal transplant in our centre and with graft survival higher than 1 year were included in the study. NODM was defined as two fasting plasma glucose values > or =126 mg/dl or symptoms of diabetes plus casual plasma glucose concentrations > or =200 mg/dl throughout the first year. We examined previously reported variables related with NODM development. The incidence of NODM at 12 months was 27.6%. Risk factors for NODM included older age, higher first tacrolimus level, higher body mass index and lower first year weight gain. In multivariate analysis, the first year occurrence of NODM was significantly determined by the first tacrolimus blood level >20 ng/ml and age older than 50 years. CDR remains significantly higher in NODM throughout the 6 months. Older age and a high first tacrolimus blood level are associated with the development of NODM during the first year after kidney transplantation. NODM patients show higher CDR during the first 6 months.
Similar articles
-
Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.Transplant Proc. 2005 Nov;37(9):3819-20. doi: 10.1016/j.transproceed.2005.09.196. Transplant Proc. 2005. PMID: 16386549
-
Diabetes mellitus after kidney transplantation: a French multicentre observational study.Nephrol Dial Transplant. 2007 Jul;22(7):1986-93. doi: 10.1093/ndt/gfm011. Epub 2007 Mar 29. Nephrol Dial Transplant. 2007. PMID: 17400559
-
Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients.Transplantation. 2007 Apr 27;83(8):1027-34. doi: 10.1097/01.tp.0000259617.21741.95. Transplantation. 2007. PMID: 17452891
-
The burden of new-onset diabetes mellitus after transplantation.Clin Transplant. 2006 Nov-Dec;20(6):755-61. doi: 10.1111/j.1399-0012.2006.00565.x. Clin Transplant. 2006. PMID: 17100726 Review.
-
New-onset diabetes after liver transplantation: from pathogenesis to management.Liver Transpl. 2005 Jun;11(6):612-20. doi: 10.1002/lt.20439. Liver Transpl. 2005. PMID: 15915488 Review.
Cited by
-
Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus.Pharmacogenomics J. 2010 Apr;10(2):120-5. doi: 10.1038/tpj.2009.44. Epub 2009 Sep 15. Pharmacogenomics J. 2010. PMID: 19752882
-
Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?Biomed Res Int. 2018 Jan 30;2018:4573452. doi: 10.1155/2018/4573452. eCollection 2018. Biomed Res Int. 2018. PMID: 29651435 Free PMC article.
-
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of Renal Transplant Patients.Ann Transplant. 2024 Apr 30;29:e943282. doi: 10.12659/AOT.943282. Ann Transplant. 2024. PMID: 38685698 Free PMC article.
-
Endoplasmic reticulum stress in the adipose tissue and monocyte chemoattractant protein-1 are involved in tacrolimus-induced diabetes mellitus.Pharmacol Res Perspect. 2023 Jun;11(3):e01081. doi: 10.1002/prp2.1081. Pharmacol Res Perspect. 2023. PMID: 37195045 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical